ClassID:

20933

A61K38/1758 - CPC Classification

Classification description:

Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53

Recent Application in this class:
#1
20250032414
2025-01-30

PHYSIOLOGICALLY ACTIVE SUBSTANCE CARRIER

#2
20240366687
2024-11-07

Probiotic method and composition for maintaining a healthy vaginal microbiome

#3
20240335508
2024-10-10

HYBRID GOLD NANOPARTICLE-LIPID NANOPARTICLES AND METHODS OF USE AND PRODUCTION THEREOF

#4
20240285697
2024-08-29

Method and system to modify an individual's gut-brain axis to provide neurocognitive protection

#5
20240277780
2024-08-22

Modulation of an Individual's Gut Microbiome to Address Osteoporosis and Bone Disease

#6
20240156878
2024-05-16

Topical application to treat acne vulgaris

#7
20240100189
2024-03-28

USING MINIVECTORS TO TREAT IDIOPATHIC PULMONARY FIBROSIS

#8
20240075099
2024-03-07

COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS

#9
20240041771
2024-02-08

Physiologically active substance carrier

#10
20240024382
2024-01-25

Method and system to modify an individual's gut-brain axis to provide neurocognitive protection

#11
20240024378
2024-01-25

Method and system for modulating an individual's skin microbiome

#12
20240016890
2024-01-18

METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING CANCER

#13
20240016856
2024-01-18

Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH

#14
20230390343
2023-12-07

Probiotic method and composition for maintaining a healthy vaginal microbiome

#15
20230364178
2023-11-16

Small Molecule Cancer Treatments that Cause Necrosis in Cancer Cells But Do Not Affect Normal Cells

#16
20230285473
2023-09-14

Modulation of an individual's gut microbiome to address osteoporosis and bone disease

#17
20230241129
2023-08-03

Probiotic to enhance an individual's skin microbiome

#18
20230218682
2023-07-13

Topical application of CRISPR-modified bacteria to treat acne vulgaris

#19
20230190955
2023-06-22

TREATMENT OF LIVER CANCER OR LIVER FIBROSIS

#20
20230172995
2023-06-08

Method and system for reducing the likelihood of developing depression in an individual

#21
20230135456
2023-05-04

CELL-DERIVED VESICLES COMPRISING WILD-TYPE P53 PROTEIN FOR ANTIVIRAL THERAPY

#22
20230131201
2023-04-27

Topical application of to ameliorate barrier damage and inflammation

#23
20230040879
2023-02-09

Method and system for reducing the likelihood of osteoporosis

#24
20220378853
2022-12-01

Method for treating individuals having cancer and who are receiving cancer immunotherapy

#25
20220331375
2022-10-20

Method for treating an individual suffering from bladder cancer

#26
20220296655
2022-09-22

Method and system for reducing the likelihood of developing colorectal cancer in an individual human being

#27
20220193150
2022-06-23

Method and System for Reducing the Likelihood of Developing Depression in an Individual

#28
20220118031
2022-04-21

Method and System to Improve the Health of a Person's Skin Microbiome

#29
20220016271
2022-01-20

METHODS FOR TREATING CANCER

#30
20210369614
2021-12-02

Physiologically active substance carrier

#31
20210283196
2021-09-16

Method for treating an individual suffering from a chronic infectious disease and cancer

#32
20210205403
2021-07-08

Small Molecule Cancer Treatments that Cause Necrosis in Cancer Cells But Do Not Affect Normal Cells

#33
20210000885
2021-01-07

Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being

#34
20210000883
2021-01-07

Method and system for reducing the likelihood of osteoporosis

#35
20200397832
2020-12-24

Method and system for reducing the likelihood of developing depression in an individual

#36
20200368316
2020-11-26

Methods and compositions for preventing or treating cancer

#37
20200330526
2020-10-22

Method for reducing the likelihood of developing cancer in an individual human being

#38
20200179460
2020-06-11

Reducing the likelihood of skin cancer in an individual human being

#39
20200113829
2020-04-16

Methods for reducing side effects of immunotherapy

#40
20200038471
2020-02-06

SMALL MOLECULE CANCER TREATMENTS THAT CAUSE NECROSIS IN CANCER CELLS BUT DO NOT AFFECT NORMAL CELLS

#41
20200009054
2020-01-09

Physiologically active substance carrier

#42
20190380957
2019-12-19

Protein Hydrogels For Treatment Of Neovascular Disease

#43
20190307813
2019-10-10

Method and system for treating cancer and other age-related diseases by extending the healthspan of a human

#44
20190298781
2019-10-03

Method of reducing the likelihood of skin cancer in an individual human being

#45
20190127431
2019-05-02

Cell-penetrating peptide

#46
20190076504
2019-03-14

COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS

#47
20190070259
2019-03-07

Methods and compositions for preventing or treating cancer

#48
20190038713
2019-02-07

COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY AND IMMUNE CHECKPOINT BLOCKADE FOR THE TREATMENT OF CANCER

#49
20190038680
2019-02-07

Method of reducing the likelihood of skin cancer in an individual human being

#50
20180360923
2018-12-20

Oncological and Neurological Therapy based on ATM, CHK2 and p53 proteins for DNA correction of transcription errors

#51
20170348359
2017-12-07

Method and system for treating cancer and other age-related diseases by extending the healthspan of a human

#52
20170173085
2017-06-22

Method and system for treating cancer cachexia

#53
20170119827
2017-05-04

Method of reducing the likelihood of skin cancer in an individual human being

#54
20170096497
2017-04-06

USE OF ANTIBODY CONJUGATES

#55
20160347806
2016-12-01

OLIGOMERIZATION DOMAIN OF P53 TO BYPASS THE DOMINANT-NEGATIVE EFFECT OF MUTANT

#56
20160339064
2016-11-24

Method and system for treating cancer cachexia

#57
20160235859
2016-08-18

Methods for DNA-dependent targeting of a cell permeant antibody

#58
20160145314
2016-05-26

Compositions comprising serum albumin and p53 peptides fusion proteins

#59
20150352179
2015-12-10

Compositions and methods involving endogenous retrovirus proteins

#60
20150164797
2015-06-18

Rice bran-lipids based formulation and process for preparation thereof for selective delivery of genes to cancer cells

#61
20120237614
2012-09-20

PEPTIDE ABLE TO DISRUPT THE PROTEIN COMPLEX BETWEEN THE HIS273 MUTADED P53 PROTEIN AND THE ONCOSUPPRESSIVE P73 PROTEIN IN TUMOR CELLS AND THERAPEUTIC USES THEREOF

#62
20120082655
2012-04-05

Downregulation of SPY1 by p53 as an essential component of p53-mediated effects

#63
20110183915
2011-07-28

Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells

#64
20100150884
2010-06-17

Anticancer Agent to Be Combined with Telomelysin

#65
20100143358
2010-06-10

Use of Antibody Conjugates

#66
20090215164
2009-08-27

Recombinant gene of adenovirus vector and p53 gene for treating proliferative diseases

#67
20080118466
2008-05-22

TREATMENT OF RHEUMATOID ARTHRITIS WITH SOLUBLE FAS-LIGAND CROSS-LINKERS

#68
20080044465
2008-02-21

THERAPY FOR CELLULAR ACCUMULATION IN CHRONIC INFLAMMATORY DISEASES

#69
20070009485
2007-01-11

Nucleic acid delivery

#70
20060160732
2006-07-20

Compositions and methods for inhibiting cell senescence and hyperproliferative disorders

#71
20050159357
2005-07-21

Treatment of rheumatoid arthritis with soluble Fas-ligand cross-linkers

#72
20050014259
2005-01-20

Nucleic acid delivery